ArticleCureus2026
Relationship Between Serum Magnesium Levels and Glycemic Control in Type 2 Diabetes Mellitus: A Case-Control Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder that represents a global health burden. Recent findings indicate that serum magnesium plays a crucial role in glucose metabolism and insulin function. Insufficient magnesium levels are associated with diminished insulin secretion and increased insulin resistance. However, region-specific data from South India, particularly Kerala, remain limited. MATERIALS AND
methodsA case-control study was conducted in the Department of Medicine of a tertiary care hospital in Kerala from November 2022 to March 2024 to compare serum magnesium levels between adults with uncontrolled and controlled T2DM and to assess the associations of serum magnesium levels with HbA1c and other clinical and biochemical variables. A total of 34 patients with uncontrolled T2DM (HbA1c >7%) and 34 patients with controlled T2DM (HbA1c ≤7%), classified according to the 2021 American Diabetes Association glycemic target guidelines, were matched by age and sex. Demographic and laboratory data were analyzed using SPSS Statistics version 25 (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY), with p < 0.05 considered statistically significant.
resultsDemographic characteristics were similar across groups. Uncontrolled cases had significantly higher HbA1c (median 8.3%, IQR 7.83-9.0 vs 6.7%, IQR 6.5-6.9; p < 0.001), fasting blood sugar (median 187.5, IQR 142-204 vs 120 mg/dL, IQR 110.25-131.75; p < 0.001), and blood pressure than controls. Hypomagnesemia occurred only in patients with uncontrolled T2DM (5/34, 14.7%); median serum magnesium was significantly lower in cases than in controls (2.1, IQR 1.9-2.3 vs 2.3 mg/dL, IQR 2.1-2.3; p = 0.018). Within cases, serum magnesium correlated inversely with triglycerides (ρ = -0.417, p = 0.014) but not significantly with HbA1c (ρ = -0.196, p = 0.266).
conclusionsSerum magnesium was lower in uncontrolled than in controlled T2DM, with hypomagnesemia only in the uncontrolled group. Within cases, magnesium correlated inversely with triglycerides but not significantly with HbA1c. Causality cannot be established given the design; larger prospective and interventional studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.